Dr Russell Thom
- BSc Medical Biochemistry, University of Glasgow
- PhD Chemistry
- Chartered Patent Attorney (UK)
- European Patent Attorney
- European Trade Mark and Design Attorney
Russell Thom’s scientific background includes a degree in medical biochemistry from the University of Glasgow and a PhD relating to the determination of the protein structure of glutathione-S-transferases to enhance herbicide selectivity. With a core expertise in the field of biotechnology, Russell has a particular focus on peptide-based therapies, nucleic acid-based therapeutics, diagnostic assays and medical devices.
He has worked extensively with universities, biotechnology companies, and large corporates, assisting them on all aspects of the patent process. This includes the assessment of initial ideas through to the delivery of a suitable patent strategy, optimised to achieve the commercial goals required.
Russell has been extensively involved with initiatives to raise IP awareness within organisations. He routinely provides seminars, workshops and IP surgeries to academics and R&D staff to promote knowledge in relation to intellectual property. He has also worked with a number of larger organisations to develop intellectual property policies covering all aspects of IP management, from initial capture and review of inventions to management processes for large intellectual property portfolios. That allows organisations to maximise the return from their intellectual assets.
Russell joined Murgitroyd in 2000 and is based in the company’s Glasgow office. He was appointed Director of Patents in 2008. As practice group leader of the company’s life sciences and chemistry team, he has a leading role in the management of the company’s life sciences and chemistry offering across Europe. He also has responsibility for risk management issues across the company.
Core Expertise: biochemistry, medical biochemistry, biotechnology, molecular biology, proteomics, structural biology, x-ray crystallography, peptide therapies, nucleic acid therapies, diagnostic assays, medical devices, life sciences, chemistry, next generation sequencing, CRISPR, and single cell processing
- Thom R. Pharmaceutical Patent Analyst. May 2012, Vol. 1, No. 2, Pages 117-119 , DOI 10.4155/ppa.12.10 (doi:10.4155/ppa.12.10) Unitary European Patent
- Thom, R., Drug Discovery Today: TARGETS. 2004 Jun; 3, 3:123-124. Patent update.
- Thom R, Cummins I, Dixon DP, Edwards R, Cole DJ, Lapthorn AJ. Biochemistry. 2002 Jun 4;41(22):7008-20. Structure of a tau class glutathione S-transferase from wheat active in herbicide detoxification.
- Thom R, Dixon DP, Edwards R, Cole DJ, Lapthorn AJ. J Mol Biol. 2001 May 18;308(5):949-62. The structure of a zeta class glutathione S-transferase from Arabidopsis thaliana: characterisation of a GST with novel active-site architecture and a putative role in tyrosine catabolism.
- Thom, R, Dixon, D, Edwards, R, Cole, D, and Lapthorn, A (2001) Structure determination of zeta class glutathione transferase from Arabidopsis thaliana. Chemico-biological Interactions, 133 . pp. 53-54.
- Lucke T, Choudhry R, Thom R, Selmer IS, Burden AD, Hodgins MB. J Invest Dermatol. 1999 Mar;112(3):354-61. Upregulation of connexin 26 is a feature of keratinocyte differentiation in hyperproliferative epidermis, vaginal epithelium, and buccal epithelium.
- Conference speaker – IP Roundtable for Life Sciences Boston April 2017
- Panel Moderator – The New Unitary Patent (UP) is Coming: Is Your European Portfolio Ready? – IP Roundtable for Life Sciences Boston April 2017
- Chaired panel discussion in relation to Global IP Strategies: Preparation, Process & Practice – Consero – IP Executive Roundtable for Life Sciences – Boston April 2018
- Speaker – Leveraging US patent prosecution in global patent prosecution – UCI – The Cove December 2018
- Panel Moderator – The importance of Due Diligence – Avoiding IP Risk during M & A – Consero – IP Forum for Life Sciences (Consero Group) December 2018
- Panel Moderator- IP Executive Roundtable for Life Sciences – Consero – Boston, March 2019